Learning Objectives
- Identify the need for combination therapy in dyslipidemia.
- Describe the barriers to reaching LDL-C goals in high-risk patients.
- Evaluate the role of combination therapy with Bile Acid Sequestrants.
- Explain the current guidelines for the treatment of patients with dyslipidemia.
Chair
Dr. Shafiq Qaadri MD, MPP
Family Physician, CME Lecturer, Medical Writer
Faculty
Dr. Jacques Genest
MD, FRCPC, FRACC
Director, Division of Cardiology, McGill University Health Centre and Royal Victoria Hospital
Robert A Hegele
MD, FRCPC, FACP, FAHA, FCAHS
Jacob J. Wolfe, Distinguished Medical Research Chair in Human Gene Function
Edith Schulich, Vinet Canada Research Chair in Human Genetics
Martha Blackburn, Chair in Cardiovascular Research
Distinguished University Professor of Medicine and Biochemistry, University of Western Ontario
Dr. Subodh Verma
MD, PhD, FRCSC, FAHA
Division of Cardiac Surgery, St. Michael’s Hospital
Professor Surgery and Pharmacology & Toxicology, University of Toronto
This program is supported by an educational grant from:
Video Information
- Post Date:April 4, 2016
